Q&A: Myeloma and Toxicities
Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

Released: March 12, 2021

Expiration: March 11, 2022

Noopur Raje
Noopur Raje, MD

Activity

Progress
1
Course Completed

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:

  • Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?
  • Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?
  • What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?
  • What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?

Presenter:

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts